Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ViRx
Cardiff, California, United Statesvirx.stanford.edu ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Preclinical
01
Overview
Viracta’s lead candidate, Nana-val—a combination of nanatinostat and valganciclovir—has advanced to Phase 2 trials for relapsed/refractory EBV+ lymphoma. The company is also running a Phase 1b/2 trial in EBV+ nasopharyngeal carcinoma and other solid tumors. Clinical results are pending; the company remains pre-revenue as of early 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeAntiviral agent (as part of combination therapy)
- Industry
- Biotech
Beyond the preview
Go deeper on ViRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViRx.